Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Liposarcoma 1Leiomyosarcoma 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Trabectedin × Clear all
NCT03074318 2022-04-29

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
35 enrolled 21 charts
Sarcoma

Leiomyosarcoma, Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡